China Resources Sanjiu Investment Quality Review (000999.SZ)

Quality score: 80/100 Valuation position: current price/base FV 0.67 Final signal: WATCHLIST

Core Conclusion

China Resources Sanjiu is WATCHLIST even though price/base FV is 0.67. The score clears the quality threshold, but the report still requires stronger mispricing evidence and balance-sheet follow-up before upgrading. Conservative/base/optimistic FV is CNY22.38/CNY38.74/CNY49.95.

Business And Quality

Five-year revenue CAGR is 19.4%, and latest-year FCF is CNY4.24bn. The 80/100 quality score reflects growth, cash conversion, and a defensible healthcare franchise, with deductions for evidence depth and balance-sheet leverage.

Financial Audit

The review uses fiscal 2021-2025 in CNY and a 1.7% CNY 10Y government-bond yield dated 2026-07-31. Five-year FCF/Net Income is 1.01 and OCF/Net Income is 1.34. Latest net debt is CNY1.80bn.

Valuation

The base FV is driven by normalized FCF and a separate deduction for net debt and other claims. Price/base FV below 0.70 is necessary but not sufficient; the thesis still needs clearer temporary-mispricing evidence.

Buy And Monitor

Current action is watchlist. Upgrade requires the same valuation discount to persist, quality score of at least 75, and fuller evidence on cash-flow durability, governance, and shareholder return. Track revenue trend, FCF/Net Income, ROIC, net debt, dividends, buybacks, and disclosure quality.

Risks

Risks include policy pressure on drug pricing, acquisition integration, goodwill or receivable risk, debt expansion, and weaker cash conversion. Two periods with FCF/Net Income below 0.60 would reduce normalized FV.

Sources

Sources are public quote and financial data platforms, company filings or IR, ChinaBond for the CNY risk-free rate, and public FX data where applicable. Research only, not personalized investment advice.